C. Filipe R. L. Pereira
Curriculum Vitae

Personal Information

Family name, First name: Ribeiro Lemos **Pereira**, **C**arlos **F**ilipe
ORCID 0000-0002-9724-1382, Researcher ID B-8438-2013, SCOPUS: 57220151696
Google Scholar profile: https://bit.ly/2QEQDnK
Date of birth: 08/01/1981 in Vila Nova de Cerveira, Portugal. Nationality: Portuguese.
Address: Division of Molecular Medicine and Gene Therapy, BMC A12, Sölvegatan 17, 221 84 Lund, Sweden.
Tel: +46-46-222-4919 Fax: +46-46-222-0568
E-mail: filipe.pereira@med.lu.se
URL for research group website: https://bit.ly/2QQrYQk and www.pereiralab.com

Field of research: Cellular Reprogramming, Hematopoiesis and Immunology

Biography

Filipe Pereira, Ph.D. is a Professor of Molecular Medicine in the Faculty of Medicine at Lund University in Sweden. Dr. Pereira is recognized for his work at the interface of cellular reprogramming and immunology and for fostering development of reprogramming-based immunotherapies.

For the last 20 years, he has contributed to the fields of cellular reprogramming and hematopoietic specification. Dr. Pereira received his Ph.D. at Imperial College London where he established cell fusion and heterokaryons to study mechanisms of reprogramming towards pluripotency. During his postdoctoral training at the Icahn School of Medicine at Mount Sinai in New York, he brought cellular reprogramming concepts to hematopoiesis for the first time. Dr. Pereira started his independent group at Lund University in 2017 and has uncovered new mechanisms underlying hematopoietic reprogramming and definitive hematopoiesis specification. He pioneered cellular reprogramming approaches in immunology by inducing dendritic cells from fibroblasts and cancer cells. This conceptual shift opened exciting opportunities to merge cellular reprogramming and cancer immunotherapy. Dr. Pereira co-founded Asgard Therapeutics, which received 36 million Euros of investment from leading European VCs to translate *in vivo* dendritic cell reprogramming to benefit cancer patients.

For his scientific accomplishments and innovation efforts, he received several notable scientific awards, including ERC Consolidator and Proof-of-Concept Grants, Swedish Research Council Consolidator Grant, Novo Nordisk Foundation Distinguished Innovator Grant and the entrepreneurship award from Mount Sinai-KiiLN. Dr. Pereira is a fellow of the Swedish Wallenberg program in Molecular Medicine and Editor-in-Chief of the journal Cellular Reprogramming. He was also awarded the prestigious Swedish Fernström Prize for young and promising researchers, the Pfizer-Portugal award for basic research, the Imperial College Emerging Alumni Leader Award 2025 and a medal of merit from his hometown in Portugal.

Education

2019/09/11 Docent in Molecular Medicine at Lund University.

2009/02/01 PhD in Biomedical Sciences, Imperial College School of Medicine, London, U.K.

Title: Epigenetic events underlying somatic cell reprogramming.

Supervisor: Dame Amanda G. Fisher. Examiners: Sir John B. Gurdon, Nobel prize in Physiology and Medicine 2012 and Prof. Malcolm Parker. Outstanding thesis accepted without modifications.

1998-2002 Graduation in Biology (4-year degree), Faculty of Sciences, University of Porto, Portugal.

1995-1998 High School Education, Escola Secundária de Valença, Portugal.

Current Positions

2022 – **Professor of Molecular Medicine**, **Regeneration, Transplantation and Repair of the Hematopoietic System, Wallenberg Molecular Medicine Fellow** – Faculty of Medicine, Lund University.

Group Leader: Cell Reprogramming in Hematopoiesis and Immunity.

Division of Molecular Medicine and Gene Therapy, Lund Stem Cell Center. Wallenberg Centre for Molecular Medicine, Lund University, Lund, Sweden.

The Wallenberg Centers for Molecular Medicine are the biggest Swedish investment to reposition Sweden as world-leading in life sciences. Wallenberg Fellows (10 at Lund University) are internationally recruited young scientists of outstanding potential. I was recruited as the top candidate for the position in the field of hematopoiesis and became full professor within 5 years.

2018 – Co-founder, head of innovation and chair of the SAB at Asgard Therapeutics – www.asgardthx.com, Lund, Sweden. Company raised 36 million euros of investment to translate *in vivo* DC reprogramming for clinical application from Johnson & Johnson Innovation, RV Invest, Novo Holdings, Industrifonden, and Boehringer Ingelheim Venture Fund).

2017 – Co-founder BRT Blood Reprogramming Technologies – www.bloodrt.com

2015 – Group leader, University of Coimbra, Portugal.

Previous positions

2019 – 2022 **Associate Professor** and Group Leader.

Faculty of Medicine, Lund University, Sweden.

2017 – 2019 **Assistant Professor** and Group Leader.

Faculty of Medicine, Lund University, Sweden.

2015 – 2017 **Assistant Professor** and Group Leader.

Center for Neurosciences and Cell Biology (CNC), University of Coimbra,

Portugal.

2010 – 2015 **Postdoctoral Fellow** at Prof. Ihor R. Lemischka and Kateri Moore laboratory.
Department of Developmental and Regenerative Biology, Icahn School of Medicine at Mount Sinai, New York, USA.

2009 – 2010 **Postdoctoral Fellow** at Prof. Amanda G. Fisher laboratory.
MRC Clinical Sciences Centre, Imperial College School of Medicine, London, UK.

2004 – 2009 **Graduate Student** at Prof. Amanda G. Fisher laboratory.
MRC Clinical Sciences Centre, Imperial College School of Medicine, London, UK.

2002 – 2003 **Research Assistant** at Dr. Fernando Arosa laboratory, Lymphocyte Biology Group.
Institute for Cellular and Molecular Cell Biology, Porto University, Porto, Portugal.

Fellowships

2017 – Wallenberg Fellow in Molecular Medicine, Lund University, Lund, Sweden.

2015 – 2017 Marie Curie International Incoming Fellowship, CNC, University of Coimbra, Portugal. (Total: 203 630€; research funding 20 000€).
Top fellowship for returning to Europe – includes independent research funding. Qualification 96.2%.

2013 – 2015 Charles H. Revson Senior Fellowship in Biomedical Science, Icahn School of Medicine at Mount Sinai, New York, USA. (Total: 181 220$; research costs 20 000$).
Top US postdoctoral senior fellowship for biomedical science – only one awarded per institution per year in the state of New York – includes independent research funding.

2010 – 2012 EMBO Long-term Postdoctoral Fellowship, Icahn School of Medicine at Mount Sinai, New York, USA (Total: 45 800$). *Prestigious European postdoctoral fellowship.*

2003 – 2008 Doctoral Fellowship from the Foundation for Science and Technology (FCT), Portugal. Part of GABBA multidisciplinary program in Biology, University of Porto, Portugal (Total: 75 000 €).
PhD Program selects 12 from >150 candidates (per year). Promotes full freedom of PhD lab choice.

Bibliometry:

Sum of publications: 74 (complete list at the end of the CV).

PubMed bibliography: https://shorturl.at/AOxP0

Number of citations: 4,299.

H-index: 28.

3 articles > 300 citations, 9 articles > 100 citations.

Corresponding/first author on 36/10 articles.



Publications in Science (1), Science Immunology (3), Cell Stem Cell (3), Developmental Cell (1), Molecular Cell (1) PNAS (2), Development (2), Genes & Development (2), Nature Communications (2), Nature Cell Biology (1), PloS Genetics (2), Cell Reports (2). 2 covers as senior and first author (Science Immunology and Cell Stem Cell) and one cover highlight (Science). Editorial comments about our work: Science (2024), Science Immunology (2018), Nature Immunology (2023, 2024), Developmental Cell (2016), Cell Stem Cell (2013), Molecular Therapy (2013), Nature Cell Biology (2012, 2024), Cellular Reprogramming (2024), Nature Review Drug Discovery (2024), Trends Immunol (2024) and Faculty of 1000 (3). 8 publications with outstanding popular press attention, top 5% of all published articles (Altmetric).

Patent families:

1. Method for programming differentiated cells into hematopoietic stem cells. **Pereira CF**, Moore KA, Lemischka IR. US9540612B2. 2013. Owned by Mount Sinai School of Medicine.
2. Compositions for reprogramming cells into dendritic cells or antigen presenting cells, methods and uses thereof. **Pereira CF**, Pires C, Rosa F. WO/2018/185709/A1. Priority date: 2017.04.07. Granted in US 11,345,891, JP 7303743, and CN ZL201880005047.3, pending in 7 additional countries. Owned by Asgard Therapeutics.
3. Compositions for reprogramming cells into plasmacytoid dendritic cells or interferon producing cells, methods and uses thereof. **Pereira CF**, Pires C, Rosa F. WO 2021/069672/A1. Priority date: 2019.10.10. Granted in Israel, pending in 10 additional countries. Owned by Asgard Therapeutics.
4. Compositions for reprogramming cells into dendritic cells type 2 competent for antigen presentation, methods and uses thereof. **Pereira CF**, Pires C, Rosa F, Oliveira L. WO 2021/105234/A1. Priority date: 2019.11.25. Granted in Israel, pending in 9 additional countries. Owned by Asgard Therapeutics.
5. Reprogramming of cells to type 1 conventional dendritic cells or antigen presenting cells. Rosa F, Zimmermannova O, Ferreira A, Ascic E, Pires C, **Pereira CF**. WO2022/243448/A1. Priority date: 2021.05.19. Owned by Asgard Therapeutics.

6. Pending – RNA-based strategies for dendritic cell reprogramming and uses thereof. Arh N, Vaz B, Rosa F, **Pereira CF**. Patent application number PCT/EP2024/08494. Priority date: 05/12/2023. Owned by Asgard Therapeutics.
7. Pending – Generation of T-cells by direct reprogramming from fibroblasts and MSC**. Pereira CF**. P10787GB. Priority date: 01/03/2022. Owned by Autolus Limited.
8. Pending – Composition for reprogramming cells into hemogenic and/or hematopoetic stem cell-like cells, methods and uses thereof. Alves R, **Pereira CF**. P1181.2PP. Priority date: 03/12/2021. Owned by Center for Neuroscience and Cell Biology (CNC).
9. Pending – Compositions, constructs and vectors for cell reprogramming (NK cell reprogramming). Caiado I, Kurochkin I, Dushime GT, Quinn ES, **Pereira CF**. WO2022129542. Priority date: 17/12/2019. Owned by Asgard Therapeutics.

Invited Presentations:

Conferences and Departmental Seminars:

2024 Seminar at the Faculty of Medicine Christmas Event. Lund University, Sweden. Invited by Maria Björkqvist.
2024 Sharon Barr (CSO of Astrazeneca) visit to SciLifeLab organized by KAW. Stockholm, Sweden. Invited by Göran Sandberg.
2024 ATMP Sweden 2024. Malmö, Sweden. Invited by Johan Flygare.
2024 Seminar at Karolinska Institute. Stockholm, Sweden. Invited by Sten Linnarsson.
2024 Molecular Hematopoiesis 27, Francis Crick Institute. London, UK. Invited by Katrin Ottersbach.
2024 reNEW, Novo Nordisk Center for Stem Cell Medicine. Copenhagen, Denmark. Invited by Kim Jensen.
2024 Cure the Incurable – Cell and Gene Therapy to Revolutionize Medicine Event, The Swedish residence, New York, USA.
2024 Seminar at New York University, New York, USA. Invited by Boris Reizis.
2024 Faculty Morning Meeting. Lund University, Sweden. Invited by Maria Björkqvist.
2024 CICON24-CRI-ENCI 8th International Cancer Immunotherapy Conference: Translating Science into Survival. Washington, MD, USA.
2024 Malmö Cancer Center Retreat. Ystad, Sweden. Invited by Maria Alvarado-Kristensson.
2024 ISEH 53rd Annual Meeting, Chicago, Illinois, USA.
2024 ISSCR 2024 Annual Meeting, Hamburg, Germany. Invited by Malin Parmar and Agnete Kirkeby.
2024 PALS Meeting, Umeå, Sweden.
2024 Seminar at Mass, Department of Molecular Biosciences, Stockholm University, Stockholm, Sweden. Invited by Kanwal Tariq.
2024 LUCC Brain seminar series, Lund, Sweden. Invited by Johan Bengzon.

2024 Seminar at Guangzhou laboratory, Guangdong Province, China. Invited by José Silva.
2024 Seminar at City University of Hong Kong, Hong Kong. Invited by Bee Luan Khoo.
2024 Seminar at The Chinese University of Hong Kong, Hong Kong. Invited by Kathy Lui.
2024 Seminar at Hong Kong University, Hong Kong. Invited by Rio Sugimura.
2024 NovoNordisk Distinguished Innovator Meeting. Hillerod, Denmark.
2023 ISSCR Cell Fate Programming Webinar, Virtual. Invited by Katie Galloway.
2023 Takara Webinar, Virtual.
2023 NYSCF Annual Meeting. Rockefeller University, NYC, USA. Invited by Raeka Aiyar.
2023 CSHL Cell Fate Conversions conference, New York, USA. Invited by Thomas Graf.
2023 Novo Nordisk Foundation Science Lecture: Distinguished Innovators, Copenhagen, Denmark.
2023 Seminar at Instituto superior técnico, Lisboa, Portugal. Invited by Simão Rocha.
2023 Seminar at Karolinska Institute, Stockholm, Sweden.
2023 Seminar at Linköping University cancer seminar series. Virtual.
2023 Spring Brain Conference, Sedona, Arizona, USA.
2023 Lund Stem Cell Centre 25th Anniversary Conference, Lund, Sweden.
2023 Portuguese Society for Immunology Annual Meeting 2023, Aveiro, Portugal.
2023 Seminar at the University of Gothenburg, Gothenburg, Sweden. 2023.
2023 Seminar at the University of Texas Health Science Center, Houston, USA. Virtual.
2023 Darwin Regional Conference, presented by STEM Community IUB. Keynote speaker. Virtual.
2022 BSRT symposium 2022, Berlin, Germany. Keynote speaker. Virtual.
2022 Seminar at Columbia University, NYC USA. Invited by Jianlong Wang.
2022 Seminar at the Icahn School of Medicine at Mount Sinai, NYC, USA. Invited by Eirini Papapetrou.
2022 ISSCR, San Francisco, USA. Invited by Malin Parmar.
2022 Seminar at Astrazeneca, Gothenburg, Sweden.
2022 Seminar at Bluepharma, Coimbra, Portugal. Invited by Sérgio Simões.
2022 Seminar at i3S, Porto, Portugal. Invited by Pedro Resende.
2022 Keynote lecture at the National Wallenberg Fellows Meeting, Ystad, Sweden. Invited by Gunila Westergren-Thorsson.
2021 Princeton Alumni Association (Princeton Propellers), Princeton, US. Invited by Barbara F Graham.
2021 Medicon Alliance, Emerging Cell and Gene Therapies, Lund, Sweden. Invited by Johan Flygare.
2021 Lunch seminar at King's College, London, UK. Invited by Jean-Francois Darrigrans.
2021 Seminar at Institute Pasteur, Paris, France. Invited by Ana Cumano.

2021 Symposium at Kumamoto University, Japan, Virtual. Invited by Kenichi Miharada and Goro Sashida.

2021 19th ERS Lung Science conference, Virtual. Invited by Herbert Schiller.

2021 Annual National Molecular Medicine Fellows meeting, virtual. Invited by Eva Åström.

2020 25th European Hematology Association (EHA) Congress, Virtual. Invited by Kimmo Porkka.

2020 Institute of Molecular Medicine, Faculty of Medicine of the University of Lisbon, Lisbon, Portugal. Invited by Sergio Almeida.

2020 Scientific Exchange Workshop between AstraZeneca & The Wallenberg Centres in Gothenburg and Lund, Mölndal, Sweden. Invited by Andy Davis.

2019 Seminar at Autolus, London, UK. Autolus is a clinical stage company that develop CAR-T cells. Invited by Martin Poule.

2019 Seminar at Bit Bio, Cambridge, UK. Bio Bit develop reprogramming strategies of human stem cells. Invited by Mark Kotter.

2019 Biotech Research & Innovation Centre, Copenhagen University, Copenhagen, Denmark. Invited by Bo Porse.

2019 Principles of pluripotent stem cells underlying plant vitality symposium, Tohoku University, Sendai, Japan. Invited by Junko Kyozuka.

2019 National Institute of Advanced Industrial Science and Technology (AIST) and Tsukuba University Medical School, Tsukuba University, Japan. Invited by Mahito Nakanishi.

2019 National Institute for Basic Biology, Okazaki University, Okazaki, Japan. Invited by Tomomi Tsubouchi.

2019 Stem Cell Talk. Invited by the Lund Stem Cell Center.

2019 Inspirational talk at the WCMM Research Day, Lund University, Lund, Sweden. Invited by WCMM.

2019 Cancer series seminar, Umeå University, Umeå, Sweden. Invited by Francesca Aguilo.

2019 Future Faculty career paths and independence seminar, Lund University, Lund, Sweden. Invited by Future Faculty.

2018 Danish single cell symposium, Novo Nordisk Foundation, Hellerup, Denmark. Invited by Konstantin Khodosevich.

2018 European Commission Expert Mission. TAIEX Regional Workshop on Biomedical Engineering – Genetics. Sarajevo, Bosnia and Herzegovina.

2018 CIMUS, University of Santiago de Compostela, Santiago de Compostela, Spain. Invited by Miguel Fidalgo.

2018 Lund Stem Cell Center, StemTherapy LU Innovation award pitch. Båstad, Sweden.

2018 Symposium in Memory and Celebration of Ihor R. Lemischka, Mount Sinai School of Medicine, NYC, USA. Invited by Marek Mlodzik & Saghi Ghaffari.

2018 Centre for genomics and oncological research, University of Granada, Granada, Spain. Invited by David Landeira.
2018 Division of Immunology, BMC D14, Lund University, Lund, Sweden. Invited by Katharina Lahl.
2018 Division of Hematology and Transfusion medicine BMC B13, Lund University, Lund, Sweden. Invited by Anna-Karin Wihlborg.
2018 Department of Laboratory Medicine, Lund University, Lund, Sweden.
2018 Department of Pathology and Immunology, School of Medicine, University of Geneva, Geneva, Switzerland. Invited by Julien Bertrand.
2017 Department of Fundamental Oncology, University of Lausanne, Ludwig Center for Cancer Research, Lausanne, Switzerland. Invited by Ping-Chih Ho.
2017 Inspirational talk. Lund Stem Cell Center Annual Retreat, Ystad Saltsjöbad, Sweden.
2017 46th Annual Scientific Meeting International Society for Experimental Hematology ISEH. 24-27 August 2017. Frankfurt, Germany.
2017 XV Congress SIC - Sociedade Iberica de Citometria. CCB, Lisbon, Portugal.
2017 Division of Molecular Medicine and Gene Therapy, University of Lund, Sweden.
2017 III Semana da Bioengenharia. Instituto Superior Técnico, Lisbon, Portugal.
2017 III – Encontro Nacional de Estudantes de Biotecnologia, Aveiro, Portugal.
2016 5º Fórum Anual de Graduados Portugueses no Estrangeiro (GraPE), Coimbra, Portugal.
2016 1st Meeting on Biomedical Research @ UC, Coimbra, Portugal.
2016 MRC Centre for Regenerative Medicine, University of Edinburgh, UK. Invited by Keisuke Kaji.
2016 Centre of Regenerative Medicine (CRMB), Barcelona, Spain. Invited by Alessandra Giorgetti.
2016 Erasmus University Medical Center, Rotterdam, The Netherlands. Invited by Frank Grosveld.
2016 II Workshop of Stem Cells, Hospitals of the University of Coimbra, Portugal.
2016 Institute for Molecular Medicine, PhD Program Meeting, Lisbon, Portugal.
2015 Cancer Research UK Manchester Institute, Manchester, UK. Invited by Georges Lacaud.
2015 CNC.IBILI Seminar, Coimbra, Portugal.
2015 Plenary Lecture. Sociedade Portuguesa Células Estaminais Anual Meeting, Oeiras, Portugal.
2015 CNC.IBILI Seminar, Cantanhede, Portugal.
2015 Charles H. Revson Foundation, New York, USA.
2015 Next Gen Stem Cell Meeting, Saratoga, USA.
2014 CNC.IBILI Annual Meeting, Coimbra, Portugal.
2014 Weatherall Institute of Molecular Medicine, Oxford, UK. Invited by Marella de Brujin.

2012 Biocant Park, Cantanhede, Portugal.
2012 Gordon Conference: Reprogramming Cell Fate, Galveston, USA.
2011 7th Royan International Congress, Tehran, Iran.
2009 HBGS symposium in Epigenetics, Helsinki, Finland.
2008 Cancer Research UK Stem Cell Meeting, London, UK.
2006 Joint UK-CIRM Stem Cell Conference, Broadway, UK.

International Advanced Schools:

2023 A-WISH Alicante Winter Immunology Symposium in Health. Alicante, Spain. Invited by Miriam Merad and Jordi Ochando.
2018 International PhD Course in Molecular Medicine. Developmental Biology: Mechanisms, Models and Applications. Milan, Italy. 50 students. Invited by Andreas Ditadi.
2016 Single Cell Analysis and High-throughput Biology, Cantanhede, Portugal.
2016 ICVS epigenetics course, Institute for Health and Life Sciences, Braga, Portugal.
2016 ICVS flow cytometry course, Institute for Health and Life Sciences, Braga, Portugal.
2015 Royan Stem Cell Summer School, Cellular Reprogramming and Hematopoiesis, Royan Institute, Tehran, Iran.

Research group:

The focus of my research is to understand the molecular determinants underlying cellular reprogramming and hematopoietic specification. We develop and apply immune cell reprogramming approaches for regenerative medicine and immunotherapy.

Current Research Group Members:

Management

2024 – Catarina Ferreira, PhD – Project Manager
2024 – Mariana Lopes, PhD – Science Writer

Postdoctoral Fellows:

2020 – Ilia Kurochkin, PhD – bioinformatician
2021 – Camila Vásquez-Echegaray, PhD
2023 – Pedro Cunha, PhD
2024 – Liliana Oliver Rios, PhD
2024 – Peng Wei, PhD
2024 – Sandra Schwarz, PhD
2024 – Camille Chatelain, PhD
2024 – Sandhya Malla, PhD
2024 – Inês Lopes, PhD

PhD students:

2019 – Inês Caiado, MSc
2021 – Nejc Arh, MSc
2021 – Luís Oliveira, MSc
2022 – Ervin Ascic, MSc
2023 – Diogo Cabral, MSc
2023 – Abigail Altman, MSc
2024 – Evelyn Halitzki, MSc
2024 – Rita Silva, MSc
2025 – Mariana Gonçalves, MSc
2025 – Beatriz Vaz, MSc
2025 – Gaia Fontanari, MSc

Research Fellows:
2022 – Malavika Nair, MSc
2023 – Daniel Oliveira, MSc
2024 – Margarida Brás, MSc
2024 – Hugo Moreira, MSc
2025 – Konstantinos Kokkoros, MSc

Technicians:
2018 – Susana Pedreiro, MSc

Supervision

Postdoctoral fellows: Cristiana Pires (2016–2021), Marta Pinto (2017–2021), Olga Zimmermannova (2018–2024), Hreinn Bennonisson (2020–2022), Ilia Kurochkin (2020–), Lavinia Romera (2021–2023), Camila Vasquez (2021–), Naga Radharani Nalukurthi (2021–2023), Pedro Cunha (2023–), Luís Rocha (2023–2024), Liliana Oliver Rios (2024–), Peng Wei (2024–), Camille Chatelain (2024–), Sandra Schwarz (2024–), Sandhya Malla (2024–) and Inês Lopes (2024–).

PhD students: Andreia Gomes (2012–2018), Fábio Rosa (2017–2021), Gabriela Ferreira (2017–2023), Rita Alves (2018–2023), Inês Caiado (2019–), Luís Oliveira (2021–), Nejc Arh (2021–), Ervin Ascic (2022–), Diogo Cabral (2022–), Abigail Altman (2023–), Evelyn Halitzi (2024–), Rita Silva (2024–), Mariana Gonçalves (2025–), Beatriz Vaz (2025–) and Gaia Fontanari (2025–).

Teaching Activities:

2023 A-WISH Alicante Winter Immunology Symposium in Health. Alicante, Spain.
2021 – Coordinator of the stem cells and regenerative medicine course at the Biomedicine Master's Program. Lund University. 25 students.
2021 – Lecturer of the stem cells and regenerative medicine course at the Biomedicine Master's Program. Lund University. 25 students.

2020 – Lecturer of the experimental design and scientific communication at the Biomedicine Master's Program. Scientific Writing workshop.

2018 – Lecturer at the WCMM Regenerative Medicine Research School on a weekly basis, including lectures, workshops, evaluations, career development, retreats, etc. Lund, Sweden. 20 students per year.

2018 – 2020 Steering board member at the WCMM Regenerative Medicine Research School. Lund, Sweden. 20 students per year.

2019 Lecturer at the Research School in Stem Cell Biology. Meet the experts: Combining Live Imaging and Automation with the Zeiss Cell discoverer 7. Lund University, Sweden. 30 students.

2018 Lecturer at the International PhD Course in Molecular Medicine: Developmental Biology: Mechanisms, Models and Applications, San Raffaele Telethon Institute for Gene Therapy, Milan, Italy. 60 students.

2018 Lecturer at RSSCB, symposium on single cell technologies in stem cell research: elucidating hematopoietic reprogramming at the single cell level.

2015 – 2017 Lecturer at the MIT-Portugal doctoral program, Cellular Reprogramming, ITQB, Nova University of Lisbon, Portugal. 12 students.

2015 – 2017 Lecturer at the PDBEB doctoral program, Cellular Reprogramming, University of Coimbra, Portugal. 12 students.

2016 Lecturer at the doctoral program in metabolism, Cellular Reprogramming and Hematopoiesis, Faculty of Medicine, University of Porto, Portugal. 6 students.

2016 Lecturer at the Cellular & Molecular Biology Master Program, Flow Cytometry, University of Coimbra, Portugal. 60 students.

2015 Lecturer at the PDBEB doctoral program Flow Cytometry, University of Coimbra, Portugal. 12 students.

Organization of Scientific Meetings:

2025 Organizer of the 10th Anniversary conference of WCMM. Lund, Sweden.

2025 Programme for Academic Leaders in Life Science (PALS) meeting for trainees. Coordinating a nationwide initiative to understand cell fate decisions. 30 participants. Rimforsa Strand Kurs & Konferens, Sweden.

2024 Organizer of "Cure the Incurable – Cell and Gene Therapy to Revolutionize Medicine", network event aiming to strengthen the connections between Lund University foundation and stakeholders in New York area, The Swedish Residence, New York, USA.

2024 2024 ISSCR Annual Meeting program committee Hamburg, Germany - New Technologies track, co-lead with Barbara Treutlein. Chair of three sessions.

2023 - Organizer of "Stem Cell Stars" monthly seminar series aiming to bring leaders in

stem cell research and regenerative medicine to Lund University.

2022 National Molecular Medicine Fellows Program meeting organizing committee. National meeting bringing together all WCMM fellows across multiple institutions. Ystad, Sweden. ~120 participants.

2020 Young Investigator "First author" symposium: Advances in stem cell research organising committee, Lund, Sweden.

2021 WCMM Research school retreat. This was a 2-day event with workshops on ethics and writing, public outreach presentation with videos prepared by the trainees and announcement of the winner of the grant writing competition. ~20 participants.

2019 Immunology Day, part of the international immunology day, Cantanhede, Portugal. Global effort to promote the benefits of immunology research during the International Day of Immunology that takes place every year on April 29**.** 50 participants.

2018 Lund stem cell center retreat, organizing committee, Båstad, Sweden. 130 participants.

2017 Immunology Day, part of the international immunology day, Cantanhede, Portugal. 50 participants.

2016 Immunology Day, part of the international immunology day, Cantanhede, Portugal. 50 participants.

2013 International Conference on Stem Cells for Drug Screening, Cantanhede, Portugal. 120 participants.

2003 GABBA international PhD program Annual Symposium: Nanotechnology and Medicine, Porto, Portugal. 60 participants.

Thesis committee Member or Opponent:

PhD Thesis Opponent (External Evaluator)

2023 Sandhya Malla, Department of Molecular Biology, Wallenberg Centre for Molecular Medicine, Umeå University, Sweden.
Thesis: Dissecting gene expression regulation in mouse embryonic stem cells.

2021 João Calmeiro, University of Coimbra, Portugal.
Thesis: Potentiation of dendritic cell phenotypic and functional characteristics for application in next-generation cancer immunotherapy.

2018 Sílvia Arroz Madeira, Faculty of Medicine University of Lisbon, Lisbon, Portugal.
Thesis: Environmental sensing by immune cells.

2017 Inês Sofia Alvarez Martins, Faculty of Medicine University of Lisbon, Portugal.
Thesis: Endothelial Notch Ligands in Bone Marrow Function and in Malignancy.

2017 Ana Francisca Silva de Lima, Faculty of Sciences and Technology, Nova University of Lisbon, Portugal.

Thesis: Biophysical modulation of cell fate through chromatin remodeling.

2015 Magdalena Bronislawa Florkowska, University of Manchester, UK.

Thesis: Direct reprogramming of murine fibroblasts to blood.

PhD Thesis Committee Member

2023 Maria Rodriguez Zebala, Lund University, Lund, Sweden.

Thesis: CRISPR Screens Identify Candidate Therapeutic Targets in Leukemia.

2023 Chairman of the defense of Zackarias Soderlund.

Thesis: Engineering the extracellular matrix to model diseases and orchestrate regeneration.

2022 Jessica Giacomoni, Lund University, Lund, Sweden.

Thesis: Exploring Direct Conversion of Human Glia into Therapeutic Neurons.

2021 Giulia Beneventi, Lund University, Lund, Sweden.

Thesis: RNA modifications and post-transcriptional control in cancer and stem cells.

2020 Sara Nolbrant, Lund University, Lund, Sweden.

Thesis: Directing and dissecting the fate of dopaminergic neurons – Multiple avenues towards cell replacement therapy in Parkinson's disease.

2017 Sandra Capellera Garcia, Lund University, Lund, Sweden.

Thesis: Programming blood cell fates.

PhD Thesis half-time control

2024 Examiner, half-time control Ph.D. student Chandramouli Muralidharan, Lund University. Title: Investigation of molecular mechanisms contributing to physiological and pathophysiological ageing in the human brain.

2022 Examiner, half-time control Ph.D. student Zain Ali, Lund University.

Title: Causal mechanisms of non-coding variation in human hematopoiesis.

2021 Examiner, half-time control Ph.D. student Maria Rodriguez Zebala, Lund University.

Title: CRISPR-screens to identify vulnerabilities and potential new therapeutic targets in leukemia.

2020 Examiner, half-time control Ph.D. student Sandhya Malla, Umeå University.

Title: Dissecting gene expression regulation in mouse embryonic stem cells.

2020 Examiner, half-time control Ph.D. student Ella Quist, Lund University.

Title: Dissecting the role of astrocytes in leukodystrophies.

2020 Examiner, half-time control Ph.D. student Hani Alsafadi, Lund University.

Title: Context dependence of Hippo pathway in Idiopathic Pulmonary fibrosis.

2017 Examiner, half-time control Ph.D. student Carla Azevedo, Lund University.

Title: Modeling alpha-synuclein pathology using stem cell-based models.

PhD thesis examiner

2024 Pilar Baldominos Flores, Biotechnology Department, Universidad Politecnica de Valencia.

Title: Study of immune resistant mechanisms in mouse models of breast cancer.

MSc Thesis Opponent in 21 occasions.

Training and relevant Courses:

2021 DUCO management training for the Faculty of Medicine, Faculty of Medicine, Lund University.

2020 WCMM advanced program "Academic Leadership", Faculty of Medicine, Lund University.

2019 2-day retreat on "Leadership and group dynamics". Research School in Stem Cell Biology, Faculty of Medicine, Lund University.

2018 Pedagogic course: Perspectives on Course Design, Lund University (3 weeks).

2018 WCMM Mentor Program with Prof. Anders Björklund. Faculty of Medicine, Lund University.

2018 Pedagogic course: Perspectives on Learning, Lund University (2 weeks).

2018 Pedagogic course: Research Supervision, Lund University (4 days).

2018 Pedagogic course: Problem-based Learning, Lund University (half-week).

2017 Swedish legislation & ethics, animal welfare and 3R. Lund University, Lund, Sweden.

2016 Advanced operator Training for BD FACSAria III, BD European Training Center, Erembodegem, Belgium.

2015 FELASA Course of Sciences in Laboratory Animals Category C (Investigator-coordinator).

2014 EMBO laboratory Management Course, Heidelberg, Germany.

Commissions of Trust:

2025 Chair of evaluation committee of Atip-Avenir Call 2025, Inserm and CNRS, France.

2024 Grant reviewer for the Research Council of Finland Proof-of-concept Grants, Finland.

2024 Grant reviewer for the Ambizione Grants, Switzerland.

2024	Grant reviewer for the National Science Center, Poland.
2023	External evaluator for the launch of the call "Establishment and operationalization of Competence Centers", in the context of the Recovery and Resilience Plan for Romania (PNRR), Romania.
2023 –	Member of the Lund Stem Cell Center steering board.
2023	External committee for recruitment of a Professor in Biomedical Innovation, Aarhus University.
2023 –	Scientific advisory board of Retro Biosciences, California USA. Company aims to induce cellular rejuvenation with cellular reprogramming.
2023 –	Abstract reviewer for ISEH.
2023 –	Abstract reviewer for ISSCR.
2022	ISSCR outstanding young investigator award committee.
2022	ISSCR Clinical Applications Track Committee and session chair of Biotech, Pharma and Academia – Bringing stem cells to patients.
2022 – 2024	Grant reviewer for the SNSF consolidator grants, Switzerland.
2022	Grant reviewer for CIFAR global challenges grant, Canada.
2022 – 2024	Technical due diligence for the European Commission EIC accelerator program related to a cancer immunotherapy project.
2021 –	LU-medfak ATMP working group. Group tasked by the medical faculty to coordinate the faculty's efforts to strengthen work related to ATMP and to increase our activity in CAMP (www.atmpsweden.se).
2021 – 2023	WCMM leadership working group. The WCMM center has rotating leadership of pre-clinical and clinical PI every 2 years. I was the pre-clinical PI representative between 2021 and 2023.
2021 – 2023	Nomination committee, Department of Laboratory Medicine, Faculty of Medicine, Lund University. The nominating committee draws up proposals for members of the department board and for the positions of Head of department and deputy head of department.
2020	Mentoring ERC Consolidator grant applicants: I have mentored 2 international candidates have both passed to step 2 of the evaluation (interviews) and one of them was awarded the grant. At Lund University I have been supporting the preparation of multiple candidates for interviews.
2020	Engaged in RQ20 evaluation of Lund University. Participation on drafting the RQ20 report and discussing with external reviewers for the Division of Molecular Medicine and Gene Therapy. At the Faculty level I was involved in meetings towards the creating of strong research environments.
2020	Panel discussion moderator of KAW foundation visit to Lund University, Sweden.
2019	Poster award committee. WCMM research group day, Lund, Sweden. Half day seminar for WCMM PIs, the post-docs, PhD students to meet-and-greet

and present your group´s research. The 3 best posters were awarded.

2018 Poster award committee chair. Decision and announcement of best poster by a PhD student and postdoc. The Stem Cell Niche, Copenhagen Biosciences Conference. Hillerød, Denmark.

2021 – Editor-in-Chief of *Cellular Reprogramming*. The only peer-reviewed journal dedicated to cellular reprogramming mechanisms, technologies and applications.

2020 Technical due diligence for Gilde Healthcare Partners, an active transatlantic investor in private life science companies based in the Netherlands. Due diligence work for one related to an innovation project in Cellular Reprogramming.

2019 – 2022 Consultancy contract with Autolus, UK; related to T cell programming.

2019 Grant reviewer for the Medical Research Council, UK.

2015 – Reviewer for Science, Nature, Cell, Nature Cell Biology, Science Immunology, Cell Stem Cell, Nature Communications, Science Advances, Nature Biomedical Engineering, Development, Stem Cell Reports, among others. Total of 50 verified reviews at Web of Science (https://bit.ly/3UaCWxS).

2018 Grant reviewer for the French National Research Agency, ANR, France.

2018 Reviewer for future faculty, postdoctoral application for the Swedish research council.

2016 Grant reviewer for FCT, cooperation grant between Portugal and India, FCT, Portugal.

2015 – 2017 Governing Board, Sociedade Portuguesa de Células Estaminais e Terapia Celular (Portuguese Society for Stem Cells and Cell Therapies).

2013 – 2017 Editorial Board Member, Cancer Reports and Reviews and International Journal of Stem Cell Research and Transplantation.

2013 – Associate Faculty Member, Faculty of 1000.

2006 – 2015 Co-Reviewer for the journals: Science, Cell Stem Cell, Nature Genetics, Journal of Cell Science, Stem Cells, Journal of Experimental Medicine, Nature Cell Biology and Nature Communications.

Memberships of Scientific Societies:

2024 – Active Member, Association for Cancer Immunotherapy CIMT.

2024 – Active Member, European Association for Cancer Research.

2020 – Active Member, ASH American Society of Hematology.

2020 – Active Member, EMDS European Macrophage & Dendritic Cell Society.

2020 – Active Member, SITC Society for Immunotherapy of Cancer.

2017 – Active Member, EHA European Hematology Association.

2017 – Active Member, AACR American Association for Cancer Research.

2015 – 2017 Governing Board, Portuguese Society for Stem Cells and Cell Therapies.
2016 – Academic Member, European Society of Gene and Cell Therapy.
2016 – Associated Member, Portuguese Society for Developmental Biology.
2015 – Associated Member, Portuguese Immunology Society.
2015 – Associated Member, Portuguese Society for Stem Cells and Cell Therapies.
2012 – 2015 Individual Member, New York Academy of Sciences.
2010 – Associated Member, International Society for Experimental Hematology.
2010 – Associated Member, International Society for Stem Cell Research.

Major Collaborations:

I have published with >160 different researchers through collaborations. My group's collaborations include:

2024 Barbara Schraml, dendritic cell function. Ludwig-Maximilians-Universitat Munchen, Germany. *1 co-authorship.*
2024 Fabian Theis, machine learning. Helmholtz Center Munich, Germany. *1 co-authorship.*
2024 – Anna-Lena Gustavsson, small molecule screening. Scilifelab, Stockholm, Sweden. *Co-PIs in 1 grant.*
2024 – Valentina Cauda, delivery of small molecules with lipid nanoparticles. Politecnico di Torino, Turin, Italy. *Co-PIs in 1 grant.*
2024 – Zlatko Janeba, medicinal chemistry. Czech Academy of Sciences, Prague, Czech Republic. *Co-PIs in 1 grant.*
2024 – Andreas Bender, molecular informatics. University of Cambridge, UK. *Co-PIs in 1 grant.*
2022 – Irina Agarkova, spheroids. InSphero AG, Schlieren, Switzerland. *1 co-authorship*
2022 – Silvia Remeseiro, chromatin organization. Umeå University, Umeå, Sweden.
2022 – Claudio Cantù, chromatin modification. Linköping University, Linköping, Sweden.
2022 – Jonas Larsson, hematopoietic stem cells. Lund University, Lund, Sweden.
2022 – Jianwen Que, lung reprogramming. Columbia University, New York, USA
2022 – Baris Tursun, reprogramming barriers screening, University of Hamburg, Hamburg, Germany
2019 – Jenny Hansson, immunopeptidomics. Lund University, Lund, Sweden. *Co-PIs in 1 grant. 1 co-authorship.*
2019 – Ewa Sitnicka, NK cell biology. Lund University, Lund, Sweden. *One ongoing collaborative project on NK cell reprogramming. Co-inventors in 1 patent.*

2019 – Cristian Bellodi, RNA modification. Lund University, Lund, Sweden. *One ongoing collaborative project on RNA modification and reprogramming.*

2018 – Göran B Jönsson, melanoma. Lund University, Lund, Sweden. *One ongoing collaborative project with reprogramming melanoma cells into cDC1.*

2018 – Inge Marie Svane, melanoma. CCIT Herlev Hospital, Copenhagen, Denmark. *Reprogramming melanoma to antigen presenting cells. 2 co-authorships.*

2018 – Katharina Lahl, dendritic cells type 2. Lund University, Lund, Sweden. *2 co-authorships.*

2018 – 2023 Michal Bassani-Sternberg, immunopeptidomics. Ludwig Cancer Center Lausanne, Switzerland. University. *1 co-authorship.*

2018 – Francesca Aguilo, Umeå University, WCMM Umeå, Sweden. *Breast and ovarian cancer reprogramming. Co-PIs in 1 grant.*

2018 – Dung-Fang Lee MD Anderson, kinases and phosphatases. MD Anderson Cancer Center, Texas, US. *One ongoing collaborative screening for kinases and phosphatases critical for dendritic cell reprogramming.*

2018 – 2023 Stephanie Hugues, tumor immunology. University of Geneva, Geneva, Switzerland. *In vivo anti-tumor immunity. 1 co-authorship.*

2018 – 2023 Kenichi Miharada, cancer cell reprogramming. Lund University, Lund, Sweden. *Cancer cell reprogramming to antigen presenting cells. 1 co-authorship.*

2018 – 2022 Stefan Karlsson, mesenchymal stem cells. Lund University, Lund, Sweden. *Gene therapy. 1 co-authorship.*

2018 – Javier Martin Gonzalez, transgenic mouse model generation. Copenhagen University transgenic facility, Copenhagen, Denmark. *1 co-authorship.*

2016 – 2018 Caetano Reis e Sousa, dendritic Cells. Francis Crick Institute, London, UK. *World renowned expert in dendritic cell biology. 1 co-authorship.*

2016 – 2023 Raquel Almeida, cancer stem cells. i3S, Porto, Portugal. *Co-PIs in 2 grants. 3 co-authorship and 1 patent.*

2015 – 2018 Lino Ferreira, vascular biology. CNC, Coimbra, Portugal. *2 co-authorships*.

2013 – 2023 Marella de Bruijn, developmental hematopoiesis. Weatherall Institute of Molecular Medicine, Oxford, UK. *2 co-authorships.*

Clinical Collaborations:

2018 – Clinical collaborators: Mattias Höglund, bladder cancer; Johan Bengzon, Glioblastoma; Markus Hansson, Multiple Myeloma; Kees-Jan Pronk Acute Myeloid Leukemia; Roland Andersson, pancreatic cancer; Malin Lindstedt and Lennart Greiff, head and neck cancer; Sandra Ingemansson, Lung cancer, Lund University, Lund, Sweden. Inge Marie Svane, Copenhagen University Hospital, Denmark. Critical for cancer biology cooperation and access to patient samples.

Collaborations with Industry:

2019 – Astrazeneca and Scilifelab (CBCS), Sweden. Small molecule screening project with Astrazeneca collection towards chemical reprogramming to the dendritic cell lineage and induced antigen presentation in vivo.

2019 – 2022 Autolus, UK. 3-year contract research agreement towards the generation of T cells from mesenchymal stem cells.

2019 – 2020 Bit Bio, UK. My lab has a collaborative project with Bit Bio and Asgard therapeutics for the generation of homogeneous populations of dendritic cells type 1 from human embryonic stem cells.

Prizes & Awards:

2025 Imperial College Emerging Alumni Leader Award 2025, UK.

2024 Pfizer-Portugal award in basic research, Portugal.

2024 European Commission ERC Proof of Concept grant, Sweden.

2023 Eric K. Fernströms Prize to young particularly promising and successful researchers.

2023 European Commission ERC Proof of Concept grant, Sweden.

2022 Novo Nordisk Distinguished Innovator award, Copenhagen, Denmark.

2022 FCT CEEC Auxiliary researcher, Portugal. Final classification of 9,9/10 (ranked #1 out of 71 applicants).

2021 Swedish Research Council Consolidator Grant award.

2020 Icahn School of Medicine at Mount Sinai KiiLN entrepreneurship award.

2020 European Commission ERC Consolidator Grant award.

2019 Medal of merit for outstanding achievements in cell reprogramming, Valença municipality, Portugal.

2017 Wallenberg Fellowship Molecular Medicine at Lund University, Lund, Sweden. 4-year tenure-track appointment with starting package.

2016 FCT Investigator Program Award, Portugal. 5-year starting grant to support own salary. Final classification of 8,6/9,0 (ranked #1 out of 102 applicants).

2016 Innocentive Challenge 9933820 by seeker Boehringer Ingelheim. Second Place Award selected from 198 international solvers. Novel Treatment Approaches to Stop the Allergic March towards Asthma.

2015 – 2017 Marie Curie International Incoming Fellowship, CNC, Universidade de Coimbra, Portugal.

2014 International Society for Experimental Hematology (ISEH), travel grant award 2014, Montreal, Canada.

2014 Icahn School of Medicine at Mount Sinai postdoctoral travel grant award 2014, New

York, USA.

2013 – 2015 Charles H. Revson Senior Fellowship in Biomedical Science, New York, USA.

2012 Icahn School of Medicine at Mount Sinai postdoctoral travel grant award 2012, New York, USA.

2010 – 2012 EMBO Long-term Postdoctoral Fellowship, Mount Sinai, New York, USA.

2009 Promega Young Life Scientist Awards finalist. Genetics, Physiological, Biochemical and Pharmacological Societies UK.

2003 – 2008 Doctoral Fellowship from FCT, Portugal.

2008 University of Helsinki Travel Award, Finland.

1995 Rotary Club Merit Award, Portugal.

Ongoing Research Support:

2025 – 2030 Knut and Alice Wallenberg Foundation. *Neoantigen Discovery with Cellular Reprogramming*. Budget: 1,500,000 SEK; total 35M SEK for 4 research groups. Lund, Sweden. Coordinator PI: Filipe Pereira.

2025 – 2028 EIC Transition Consortium Grant. *Repro-TIL: Breakthrough Neoantigen-specific Tumor-Infiltrating Lymphocyte Therapies Through Novel Dendritic Cell Reprogramming.* Budget: 825,000€; total 2.5M€ for 2 research groups and 1 company. Lund, Sweden. Coordinator: Asgard Therapeutics.

2024 – 2026 LUCC BLGT. *In vivo Dendritic Cell Reprogramming as a Novel Immunotherapy Strategy for Hepatocellular Carcinoma*. Budget: 499,998 SEK (49,999€). Lund, Sweden. PI: Filipe Pereira.

2024 – 2025 Vinnova - Towards deeper collaboration with UK and USA partners within Health and Life Science. *A Glioblastoma Immunotherapy Modality based on Dendritic Cell Reprogramming in vivo*. Budget: 1,000,000 SEK (100,000€). Lund, Sweden. PI: Filipe Pereira.

2024 – 2026 ERC Proof of Concept grant. *DART: Driving Tumor Antigen Presentation by RNA-mediated Transdifferentiation*. Budget: 150,000€. Lund, Sweden. PI: Filipe Pereira.

2024 – 2026 EIC Pathfinder Consortium Grant. *RESYNC: Functional chemical reprogramming of cancer cells to induce antitumor immunity*. Budget: 850,000€; total 3.3M€ for 5 research groups and 1 company. Lund, Sweden. Coordinator PI: Filipe Pereira.

2024 – 2026 Swedish cancer society (Cancerfonden) research project: *In vivo Dendritic Cell Reprogramming for cancer immunotherapy*. Budget: 4,500,000 SEK (450,000€). Lund, Sweden. PI: Filipe Pereira.

2023 – 2025 Novo Nordisk Distinguished Innovator grant. *REPROcode: a single-cell platform to define transcription factors for immune cell reprogramming*. Budget: 9,000,000 SEK (900,000€). Lund, Sweden. PI: Filipe Pereira.

2023 – 2025 FCT project DC1drug. *Using dendritic cell reprogramming to identify novel immunotherapy targets.* Budget: 249,000€. Coimbra, Portugal. PI: Filipe Pereira.

2023 – 2025 P2020 PRR: *Technological Hub for Innovation, Translation and Industrialization of Complex Injectable Drugs (CINTech).* Budget: 460,000,000 SEK (46,000,000€). Coimbra, Portugal. Co-PI: Pereira 4% of funding (2,000,000€).

2023 – 2026 ALF funding for medical research: *Developing a Cancer Immunotherapy Based on In Vivo Reprogramming of Tumors to Dendritic Cells.* Budget: 3,584,000 SEK (350,000€). Lund, Sweden. PI: Filipe Pereira.

2021 – 2026 Swedish Research Council (VR) consolidator grant: *Inducing antigen presentation in tumor cells with direct cell reprogramming.* Budget: 9,800,000 SEK (980,000€). Lund, Sweden. PI: Filipe Pereira.

2020 – 2025 ERC Consolidator grant: *Harnessing Dendritic Cell Reprogramming for Cancer Immunotherapy.* Budget: 2,000,000€. Lund, Sweden. PI: Filipe Pereira.

Past Research Grants:

2023 – 2024 ERC Proof of Concept grant. *NeoIDC: Neoantigen Identification with Dendritic Cell Reprogramming*. Budget: 150,000€. Lund, Sweden. PI: Filipe Pereira.

2021 – 2024 European Eurostars consortium grant. *Reprogramming tumors into immune cells: a revolutionary gene therapy to treat cancer*. Budget: 2,100,000€. Lund, Sweden. Co-PI: Pereira 11% of funding (240,000€).

2021 – 2023 Swedish cancer society (Cancerfonden) research project: *Understanding Dendritic Cell Diversity with Cell Reprogramming.* Budget: 3,000,000 SEK (300,000€). Lund, Sweden. PI: Filipe Pereira.

2021 – 2023 FCT project DiverDC. *Elucidating dendritic cell diversity with cell reprogramming.* Budget: 249,000€. Coimbra, Portugal. PI: Filipe Pereira.

2021 – 2023 Mats Paulsson foundation for research, innovation and community development: *Harnessing Dendritic Cell Reprogramming for Cancer Immunotherapy.* Budget: 2,000,000 SEK (200,000€). Lund, Sweden. PI: Filipe Pereira

2019 – 2020 Novo Nordisk Pioneer Innovator grant extension. *Generating NK cells by Direct Cell Reprogramming.* Budget: 500,000 DKK (67,000€). Lund, Sweden. PI: Filipe Pereira.

2020 – 2021 Novo Nordisk pre-seed grant: *Dendritic Cell Therapy.* Budget: 3,500,000 DKK (500,000€). Lund, Sweden. PI: Filipe Pereira.

2019 – 2022 Sponsored research contract from Autolus UK: *Generating T Cells from Fibroblasts and Mesenchymal Stem Cells.* Budget: 1,000,000€. Lund, Sweden. PI: Filipe Pereira.

2018 – 2019 WCMM NMMP grant 2019. *Dendritic Cellular Reprogramming: a Novel Therapeutic Strategy for Breast Cancer Patients*. Francesca Aguillo and Filipe Pereira (co-PIs). Budget: 45,000 SEK (4,500€). Lund, Sweden.

2019 – 2022 Swedish Research Council (VR) research project: *Generating Dendritic Cells by Direct Cell Reprogramming.* Budget: 4,800,000 SEK (480,000€). Lund, Sweden.

PI: Filipe Pereira.

2019 – 2021 Olle Engkvist Byggmästare research project: *Elucidating the Mechanisms of Hematopoietic Reprogramming.* Budget: 2,000,000 SEK (200,000€). Lund, Sweden. PI: Filipe Pereira.

2018 – 2021 FCT project ReproDC. *Generating Antigen Presenting Cells by Direct Reprogramming.* Budget: 238,000€. Coimbra, Portugal. PI: Filipe Pereira.

2018 – 2021 FCT project ReProgram. *Reconstructing the Genetic Program of Gastric and Colorectal Cancer Stem Cells*. Budget: 240,000€. Coimbra, Portugal. PI: Raquel Almeida. Co-PI: Filipe Pereira 25% of funding - 60,000€.

2018 – 2020 Swedish cancer society (Cancerfonden) research project: *Generating Dendritic Cells by Direct Reprogramming.* Budget: 2,400,000 SEK (240,000€). Lund, Sweden. PI: Filipe Pereira.

2019 – 2020 Novo Nordisk Pioneer Innovator grant. *Generating NK cells by Direct Cell Reprogramming.* Budget: 500,000 DKK (67,000€).

2019 – 2020 StemTherapy Methods Grant. Mass spectrometry-based immunopeptidomic profiling in stem cells, disease and reprogramming. Budget: 300,000 SEK (30,000€). Co-PI: Filipe Pereira 50% of funding - 15,000€.

2019 – 2020 Crafoord foundation research project. *Inducing anti-tumor Immunity with Dendritic Cell Reprogramming.* Budget: 400,000 SEK (40,000€). Lund, Sweden. PI: Filipe Pereira.

2017 – 2023 4-year career package: Wallenberg Centre for Molecular Medicine and Faculty of Medicine at Lund University. Total Budget: 21,500,000 SEK (2,150,000€). Lund, Sweden. PI: Filipe Pereira.

2017 – 2020 FCT PAC consortium CANCEL_STEM. *Tackling CANcer STEM CELls: a challenge and an opportunity to advance in anti-cancer therapy*. Budget: 2,000,000€. Coimbra, Portugal. Co-PI: Filipe Pereira 5% of funding - 103,695€.

2018 – 2019 Novo Nordisk Exploratory pre-seed grant. *Developing a New Cancer Immunotherapy Based on Cell Reprogramming.* Budget: 500,000 DKK (67,000€).

2018 – 2019 StemTherapy Lund Innovation award. *Developing TrojanDC a Cancer Immunotherapy Based on Direct Cell Reprogramming* Budget: 300,000 SEK (30,000€). Lund, Sweden. PI: Filipe Pereira.

2018 – 2019 Crafoord foundation research project. *Generating Dendritic Cells by Direct Reprogramming.* Budget: 300,000 SEK (30,000€). Lund, Sweden. PI: Filipe Pereira.

2018 – 2019 AAC nº 04/SAICT/2017 grant for protecting intellectual property. Budget: 50,000€.

2016 – 2019 FCT project PTDC/BIM-MED/0075/2014. *Mechanisms underlying hemogenic induction in human fibroblasts*. Budget: 199,687€. Coimbra, Portugal. PI: Filipe Pereira.

Total funding raised by my research group since 2015 in grants (including EIC Pathfinder, ERC Consolidator and Proof of Concept Grants, VR, Cancerfonden, Novo Nordisk), institutional support WCMM Lund, PhD and postdoctoral scholarships, travel awards, innovation and intellectual property exceed **20 million Euros.**

Public Engagement:

2025	Interview for the ImmunoTalks Podcast, directed by Bruno Silva-Santos and Sociedade Portuguesa de Imunologia (SPI).
2024	Interview to "Sociedade Portuguesa de Imunologia (SPI)", featuring the 2024 Pfizer Award Distinction. https://www.spimunologia.org/news/interview-filipe-pereira/
2024	Articles in "Público", "Expresso" and "Diário de Coimbra", Portuguese national newspapers featuring the 2024 Pfizer Award Distinction. https://www.publico.pt/2024/11/13/ciencia/noticia/estudo-mecanismos-cancro-formacao-retina-recebem-premios-pfizer-2024-2111562 https://expresso.pt/iniciativaseprodutos/projetos-expresso/2024-11-19-projetos-de-investigacao-basica-e-clinica-foram-distinguidos-nos-premios-pfizer-d0b4824e https://www.diariocoimbra.pt/2024/11/13/premios-pfizer-distinguem-investigacao-liderada-por-filipe-pereira-do-cnc-uc/
2024	Highlight on the Knut and Alice Wallenberg Foundation grant, Lund University News page. https://www.lunduniversity.lu.se/article/three-lund-researchers-awarded-knut-and-alice-wallenberg-foundation-grants
2024	News article at Lund University page, featuring the group's findings on the reprogramming of tumor cells into cancer-fighting immune cells in vivo. https://www.stemcellcenter.lu.se/article/researchers-reprogram-tumor-cells-cancer-fighting-immune-cells-living-beings
2024	Articles in "Público" and "Expresso", Portuguese national newspapers featuring Asgard Therapeutics investment round of 30 million euros. https://www.publico.pt/2024/04/27/ciencia/noticia/cavalo-troia-cancro-vale-30-milhoes-euros-equipa-portuguesa-2088206 https://expresso.pt/economia/empresas/2024-03-14-Biotecnologica-fundada-por-cientistas-portugueses-angaria-30-milhoes-para-tratamento-do-cancro-b4bd32d1
2024	ISSCR Member Spotlight. https://www.isscr.org/isscr-news/member-spotlight-filipe-pereira-phd
2023	Highlight on the Eric K. Fernström Prize for Young Researchers award, Lund University News page. https://www.medicine.lu.se/article/filipe-pereira-awarded-eric-k-fernstrom-prize-young-researchers
2023	News article at Lund University page, featuring the group's findings in hematopoiesis. https://www.lu.se/artikel/dna-bokmarke-hjalper-blodceller-minnas-vilka-de-ar

2022 News article at Lund University page, featuring the development of new trojan horse immunotherapy based on cell reprogramming. https://www.lunduniversity.lu.se/article/reprogramming-cancer-cells-immune-defenders

2022 News article at Lund University page, featuring the group's findings on the mechanistic insights of cDC1 specification and reprogramming. https://www.stemcellcenter.lu.se/article/new-findings-indicate-ways-increase-efficiency-reprogrammed-immune-cells

2021 First episode of the Immunology Podcast, Stem Cell Technologies. https://www.youtube.com/watch?v=5pjqhCnZkh8

2020 Meet this week's Wallenberg Researcher, Lund University News page. https://www.medicine.lu.se/article/meet-weeks-wallenberg-researcher-filipe-pereira

2020 Interview and article in "Visão" featuring emerging immunotherapies. Visão is a Portuguese weekly major news magazine. The article featured the development of new trojan horse immunotherapy based on cell reprogramming.

2020 Asgard Therapeutics' co-founders (myself, Cristiana Pires and Fabio Rosa) were featured in the cover of the magazine Pharma Industry. Asgard Therapeutics was highlighted as a life sciences company developing an ATMP product in Sweden. The report can be found here: https://lnkd.in/ew_Yggr.

2020 Development of an animation video with Kimchi studios (Barcelona, Spain) explaining dendritic cell reprogramming and the development of reprogramming of cancer cells into dendritic cells leading to an immunotherapy for cancer. https://app.frame.io/presentations/ba0fc8e9-4883-433d-99d2-ff5dc3e90d0e

2020 Development of illustrations with Scistories (Boston, US) for my laboratory research lines. The target audience are scientists, funding bodies and the general public. These were included in my laboratory website www.Pereiralab.com.

2019 Article at Lund University news page, highlighting the ERC Consolidator Grant achievement (in swedish) https://www.lu.se/artikel/21-miljoner-till-innovativ-immunterapiforskning

2019 – I am active in Twitter through the Cell Reprogramming Pereira Lab account @CellReproLab. Here, all the publications, presentations, new members and scientific opinions related are made public.

2018 Video about the group's research work. https://www.lunduniversity.lu.se/article/watch-code-reprogramming-immune-sentinels

2018 Article at Lund University news page, featuring the group's work on the conversion of human skin cells into blood stem cells (in swedish). https://www.lu.se/artikel/sa-kan-hudceller-bli-blodstamceller-mekanism-kartlagd

2018 Article in "Sábado" a major Portuguese news magazine featuring top 25 Portuguese

researchers under 40 that hold the potential to change healthcare.

2016 Contribution to ART LAB, Science Xplore. A six-day summer science and art workshop for high school students, Viseu, Portugal.

2016 Interview at Porto Canal (regional TV channel) for the program "Mentes que brilham" (bright minds). Interview conducted at the regional station studios in Porto, Portugal.

2016 Article in "Observador" Portuguese national newspaper featuring our research. https://observador.pt/2016/03/08/descobertas-as-maes-das-celulas-estaminais-do-sangue/

2016 Interview to RTP (National TV channel), Coimbra, Portugal.

2016 Interview featuring the discovery of the "mothers of blood stem cells" for the major national TV channel "SIC". https://sicnoticias.pt/pais/2016-03-09-Portugueses-descobrem-a-origem-das-celulas-estaminais-do-sangue

2016 Interview for the major Portuguese radio station "Antena 1" featuring the discovery of the "mothers of blood stem cells".

2016 Interview to RUC (Local radio), Coimbra, Portugal.

2016 – 2019 Yearly lecture to high school students and teachers: Células Estaminais do Sangue: a fonte das células imunitárias. Cantanhede, Portugal. 3 hours.

2015 European Researchers' Night: exploring science whilst having fun, Museum of Science, Coimbra, Portugal.

2015 Contribution to "Saberás tu" journal, Ciência Viva Program, Lisbon, Portugal.

2015 Lecture to high school students and teachers at the advanced course in stem cells, Instituto de Educação e Cidadania, Mamarrosa, Portugal.

2008 CORDIS documentary on epigenetics "The hidden life of our genes", London, UK.

2008 Royal Albert Hall Exhibition, "Scopic", inter-disciplinary educational initiative for school students, engaging them in both the sciences and the arts, London, UK.

2005 "Genes talking" live sequencing lab Institute of Contemporary Arts, London, UK.

Entrepreneurship:

Start-ups

2024 – Asgard Therapeutics closed an investment round of **30 million euros** Series A round co-led by RV Invest (DE) and Johnson & Johnson Innovation – JJDC, Inc., with strong participation of the 3 Seed investors. The proceeds are supporting CMC and GMP process development as well as completion of the pre-clinical package of the lead candidate AT-108, including safety and GLP toxicity studies, aiming to be ready to start First-in-Human trials by end of 2026. In addition, the company is focusing on expanding the reprogramming pipeline with new cell fates and new modalities as well as solidifying its development team.

2021 – Asgard Therapeutics attracted **6 million euros** Seed round co-led by Novo Holdings (DK), Boehringer Ingelheim Venture Fund (DE) and Industrifonden (SE). The proceeds have been used to achieve proof of concept in ex-vivo translational and in-vivo models and to select the lead candidate AT-108 (results published in the journal *Science*).

2021 – Attracted 1.2 million euros in non-dilutive funding directly to Asgard Therapeutics.

2018 – Co-founder of Asgard Therapeutics AB (asgardthx.com).

2017 – Co-founder of BRT Blood Reprogramming Technologies, Lda (bloodrt.com).

Awards and Honors

2024 J&J JLABS Global CEO Summit 2024 – Breakthrough Award. Recognizing a company that has achieved pivotal milestones in their scientific development this year. This award celebrates teams who have demonstrated exceptional leadership, vision, and dedication to pushing the boundaries of scientific understanding.

2024 European Lifestars Awards 2024 – Nomination for Biotech Company of the Year and Women-Led Business Leader of the Year.

2024 EIC Scaling Club – member of the New Biotech Platforms group.

2022 Årets Nybyggare national finalist and winner in south region. Awarded with the prize Årets Nybyggare (Settler of the Year) in the category Årest Nystart in the South region. This prize acknowledges foreign entrepreneurs that recently moved to Sweden and started their own company.

2022 Nordic Life Science (NLS) Days Invest Rising Stars, runner-up best pitch award. 40 Nordic companies selected to pitch at the NLS Days 2022. 10,000 SEK, 6 hours of free consulting, video promotion by Labiotech and free registration for NLS Days 2023.

2021 Horizon2020 Eurostars project *REPRogramming tumors INTo immune cells: a revolutionary gene therapy to treat cancer* (REPRINT, E!115376). 2,050,152 €. Consortium Coordinator.

2021 – Swelife Vinnova Collaborative project for better health 2021 to support *Turning head and neck cancer into immune cells: preclinical validation and clinical plan of TrojanDC*. 1,050,000 SEK (102,890 €).

2021 – Vinnova Verification Grant to develop an intangible asset strategy for Smile Incubator companies. 100,000 SEK (9,800 €).

2020 – LU Sparbanken Skåne Innovation Award to support future innovations spinning-out of Lund University. *TrojanDC – Turning Tumors into Immune Cells: A Revolutionary Gene Therapy to Treat Cancer.* 50,000 SEK (4,831 €).

2020 – Vinnova Innovative Startups Step 2 2020 to support *Technical and commercial development plan for Trojan DC gene therapy against cancer*. 800,000 SEK (73,470 €).

2019 – Lund University Innovation VFT+ Funds for continuation of the verification activities of the project *Reprogramming of Fibroblasts into Antigen-Presenting Dendritic Cells* towards partners, customers and investors. 400,000 SEK (36,740 €).

2019 – Horizon 2020 SME instrument Phase 1 Grant for the project proposal *TrojanDC – Turning Tumors into Immune Cells: A Revolutionary Gene Therapy to Treat Cancer*. 50,000 €.

2019 – Nordic Mentor Network for Entrepreneurship (NOME) Annual Meeting and Start-up competition. Best Pitch Award. 50,000 DKK (6,500€) and access to the mentoring program.

2019 – BIOEurope Start-up Slam pitch competition promoted by J&J Innovation – JLabs. Audience choice winner. BIOEurope 2019 meeting, Hamburg, Germany.

2019 – IPA4SME support for intellectual property (IP) valorisation and protection. COSME program. Up to 15.000 €.

2019 – Sten K Johnson Stiftelse entrepreneurship award, Medicine category for the project *TrojanDC - developing an off-the-shelf immunotherapy to turn cancer against itself.* 150,000 SEK (14,250 €).

2019 – Lund University Innovation IKS Accelerator grant. 300,000 SEK (28,500 €).

2019 – Lund University Innovation VFT Funds for verification activities of the project *Reprogramming of Fibroblasts into Antigen-Presenting Dendritic Cells* towards partners, customers and investors. 270,563 SEK (25,703 €).

2018 – Vinnova Innovative Startups to support *Regulatory and IP strategy for TrojanDC cancer gene therapy*. 300,000 SEK (28,500 €).

2018 – StemTherapy Lund Innovation award 2018 for the project *Developing TrojanDC, a cancer immunotherapy based on direct cell reprogramming*. 300,000 SEK (28,500€).

2017 – European Commission Seal of Excellence for the project proposal *MiStem - Revolutionizing Transplantation Treatment of Blood Cancers: Direct Reprogramming of Skin Cells into Blood Stem Cells* submitted under the Horizon 2020's SME instrument phase 2 call in the area of SMEInst-05-2016-2017.

2017 – Entrepreneurship competition Montepio Acredita Portugal – Health Prize 2017.

2016 – Business Plan Competition Arrisca C 2016 – promoted by University of Coimbra and other scientifica/industrial partners from Coimbra; prize of 50 000€.

<u>Accelerator programs</u>

2016 – Montepio Acredita Portugal promoted by the bank Montepio and Associação Acredita Portugal (4 weeks).

2016 – Ineostart promoted by Instituto Pedro Nunes, University of Coimbra (over 80

hours).

2015 – COHiTEC training program in technology commercialization promoted by COTEC Portugal (100 hours of classroom classes and seminars; support by management students and mentors, who contribute with their management skills, experience and networking to the development of the project; meetings with professors from the North Carolina State, Brown and Rutgers Universities).

Partners

2022 – National Center for Cancer Immune Therapy (CCIT-DK) – Collaboration with Dr. Inge Marie Svane. Validation of TrojanDC in primary melanoma cells.

2021 – 2024 Antineo, Lyon, France. CRO in vivo immune-oncology assays and 3D Bioprinting.

2021 – 2024 Insphero, Geneva, Switzerland. CRO cancer organoids and immunology assays.

2020 – Member of Smile Incubator, Lund, Sweden. Life sciences incubator, access to facilities, funding and business support.

Complete list of publications

Peer-reviewed original articles:

1. Narasimhan H, Richter ML, Shakiba R, Papaioannou NE, Stehle C, Rengarajan KR, Ulmert I, Kendirli A, La Rosa C, Kuo P, Altman A, Münch P, Saba M, Küntzel V, Sayed A, Stange EL, Pes J, Antonova AU, **Pereira CF**, Klein L, Dudziak D, Colonna M, Torow N, Hornef MW, Clausen BE, Kerschensteiner M, Lahl K, Romagnani C, Colomé-Tatché M, Schraml BU. RORγt-expressing dendritic cells are functionally versatile and evolutionarily conserved antigen presenting cells. *PNAS* 2025 *in press*.

2. Ascic E, Åkerström F, Nair MS, Rosa A, Kurochkin I, Zimmermannova O, Catena X, Rotankova N, Veser C, Rudnik M, Ballocci T, Schärer T, Huang X, Torres MR, Renaud E, Santiago MV, Met O, Askmyr D, Lindstedt M, Greiff L, Ligeon LA, Agarkova I, Svane IM, Pires CF, Rosa FF, **Pereira CF**. In vivo reprogramming of dendritic cells for cancer immunotherapy. *Science* 2024 Sep 5:eadn9083.
   Perspective in *Science* 2024 Oct;386(6719):274-275. 10.1126/science.ads6228.
   Highlighted at *Science* cover issue October 2024.
   Highlighted in *Science Adviser*. https://shorturl.at/zA8Eo.
   Highlighted in *Trends Immunol* 2024; Nov 21:S1471-4906(24)00279-5.
   Highlighted in *Nat Cell Biol* 2024;26, 1629.
   Highlighted in *Nat Genetics* 2024 Oct;56:1999.
   Highlighted in *Nature Immunology* 2024 Oct;25(10):1770.
   Highlighted in *Nat Rev Drug Discov* 2024 Oct 8.10.1038/d41573-024-00168-3.
   News & Views in *Cell Reprogram* 2024 Oct; 10.1089/cell.2024.0077.
   Highlighted by AACR, https://shorturl.at/3GVVl.

Highlighted by ACIR Accelerating Cancer Immunotherapy Research, https://shorturl.at/OAFHY.

3. Pádua D, Figueira P, Pombinho A, Monteiro I, **Pereira CF**, Almeida R, Mesquita P. HMGA1 stimulates cancer stem-like features and sensitivity to monensin in gastric cancer. *Experimental Cell Research* 2024 Sep 442(2):114257.

4. Xiao H, Ulmert I, Bach L, Huber J, Narasimhan H, Kurochkin I, Chang Y, Holst S, Mörbe U, Zhang L, Schlitzer A, **Pereira CF**, Schraml BU, Baumjohann D, Lahl K. Genomic deletion of Bcl6 differentially affects conventional dendritic cell subsets and compromises Tfh/Tfr/Th17 cell responses. *Nature Communications* 2024 Apr 30;15(1):3554.

5. Pádua D, Figueira P, Pinto M, Maia AF, Peixoto J, Lima RT, Pombinho A, **Pereira CF**, Almeida R, Mesquita P. High-Throughput Drug Screening Revealed That Ciclopirox Olamine Can Engender Gastric Cancer Stem-like Cells. *Cancers* 2023 Sep 3;15(17):4406.

6. Silvério-Alves R, Kurochkin I, Rydström A, Haider J, Rode C, Thelaus L, Lindgren AY, Ferreira AG, Brandão R, Larsson J, Brujin MFTR, Martin-Gonzalez J, **Pereira CF**. GATA2 mitotic bookmarking is required for definitive haematopoiesis. *Nature Communications*. 2023 Aug 14(1), 4645.

7. Zimmermannova O, Ferreira AG, Ascic E, Kurochkin I, Santiago MV, Hansen M, Caiado I, Shapiro E, Michaux J, Humbert M, Soto-Cabrera D, Eceiza A, Benonisson H, Silvério-Alves R, Gomez-Jimenez D, Bernardo C, Bauden M, Andersson R, Höglund M, Miharada K, Nakamura Y, Rosa FF, Pires CF, Greiff L, Lindstedt M, Hugues S, Bassani M, Svane IM, **Pereira CF**. Restoring Tumor Immunogenicity with Dendritic Cell Reprogramming. *Science Immunology* 2023 Jul 14;8(85):eadd4817.
   Highlighted in *Nature Immunology* 2023 Aug;24(8):1211.
   Highlighted by ACIR Accelerating Cancer Immunotherapy Research. http://bit.ly/45fZQtl
   Recommended by Solheim J: H1 Connect 30 Aug 2023; 10.3410/f.742707200.793600643.

8. Rosa F, Pires CF, Kurochkin I, Halitzki E, Zahan T, Arh N, Zimmermannová O, Ferreira AG, Li H, Karlsson S, Scheding S, **Pereira CF**. Single-cell transcriptional profiling informs efficient reprogramming of human somatic cells to cross-presenting dendritic cells. *Science Immunology* 2022 Mar 4;7(69):eabg5539.

9. Pádua D, Pinto DF, Figueira P, **Pereira CF**, Almeida R, Mesquita P. HMGA1 Has Predictive Value in Response to Chemotherapy in Gastric Cancer. *Current Oncology* 2021 Dec 23;29(1):56-67.

10. Jassinskaja M, Pimková K, Arh N, Johansson E, Davoudi M, **Pereira CF**, Sitnicka E, Hansson J. Ontogenic shifts in cellular fate are linked to proteotype changes in lineage-biased hematopoietic progenitor cells. *Cell Reports* 2021 Mar 23;34(12):108894.

11. Pádua D, Barros R, Amaral AL, Mesquita P, Freire AF, Sousa M, Maia AF, Caiado I, Fernandes H, Pombinho A, **Pereira CF**, Almeida R. A SOX2 Reporter System Identifies Gastric Cancer Stem-Like Cells Sensitive to Monensin. *Cancers* 2020 Feb; 12(2):495.

12. Daniel MG, Sachs D, Bernitz JM, Fstkchyan Y, Rapp K, Satija N, Law K, Patel F, Gomes AM, Kim HS, **Pereira CF**, Chen B, Lemischka IR, Moore KA. Induction of human hemogenesis in adult fibroblasts by defined factors and hematopoietic coculture. *FEBS Letters* 2019 Dec;593(23):3266-3287.

13. Rosa FF, Pires CF, Kurochkin I, Ferreira AG, Gomes A, Palma LG, Shaiv K, Solanas L, Azenha C, Papatsenko D, Schulz O, Reis e Sousa C, **Pereira CF**. Direct Reprogramming Fibroblasts into Antigen-Presenting Dendritic Cells. *Science Immunology* 2018 Dec 7;3(30):eaau4292.
    Cover *Science Immunology* issue December 2018.
    Preview by Yona & Mildner, Science Immunology, 2018 Dec 7;3(30):eaau4292.

14. Gomes A, Chang B, Kurochkin I, Daniel M, Law K, Satija N, Lachmann A, Wang Z, Ferreira L, Ma'ayan A, Chen B, Papatsenko D, Lemischka IR, Moore KA, **Pereira CF**. Cooperative Transcription Factor Induction Mediates Human Hemogenic Reprogramming. *Cell Reports* 2018 Dec 4;25(10):2821-2835.e7.

15. Freire AG, Waghray A, Soares-da-Silva F, Resende TP, Lee DF, **Pereira CF**, Nascimento DS, Lemischka IR, Pinto-do-Ó P. Transient HES5 Activity Instructs Mesodermal Cells toward a Cardiac Fate. *Stem Cell Reports* 2017 Jul 11; 9(1): 136–148.

16. Vazão H, Rosa S, Barata T, Costa R, Pitrez PR, Honório I, de Vries MR, Papatsenko D, Benedito R, Saris D, Khademhosseini A, Quax PH, **Pereira CF**, Mercader N, Fernandes H, Ferreira L. High-throughput identification of small molecules that affect human embryonic vascular development. *Proc Natl Acad Sci USA* 2017 Apr 11;114(15):E3022-E3031.

17. **Pereira CF***, Chang B, Gomes A, Bernitz B, Papatsenko D, Niu X, Swiers G, Azzoni E, de Brujin MFTR, Schaniel C, Lemischka IR, Moore K.A. Hematopoietic Reprogramming In Vitro Informs In Vivo Identification of Hemogenic Precursors to Definitive Hematopoietic Stem Cells. *Developmental Cell* 2016 Mar 7; 36(5): 525-539. *corresponding author.
    Preview by Calvanese & Mikkola, 2016.

18. Waghray A, Saiz N, Jayaprakash AD, Freire AG, Papatsenko D, **Pereira CF**, Lee DF, Brosh R, Chang B, Darr H, Gingold J, Kelley K, Schaniel C, Hadjantonakis AK, Lemischka IR. Tbx3 Controls Dppa3 Levels and Exit from Pluripotency toward Mesoderm. *Stem Cell Reports* 2015 Jul 14;5(1):97-110.

19. **Pereira CF***, Chang B, Qiu J, Niu X, Papatsenko D, Hendry CE, Clark NR, Nomura-Kitabayashi A, Kovacic JC, Ma'ayan A, Schaniel C, Lemischka IR, Moore K. Induction of a hemogenic program in mouse fibroblasts. *Cell Stem Cell* 2013 August 1; 13 (2), 205-18. *corresponding author.

Cover *Cell Stem Cell* issue August 2013. Preview by Pfaff & Cantz, 2013.
Highlighted in Molecular Therapy *21*, 1291 (2013).
Highlighted in Stem Cells Translational Medicine News section June 2013.
Highlighted in a Direct Reprogramming timeline by Xu et al, Cell Stem Cell 2015.
Recommended by the Faculty of 1000.

20. Fidalgo M, Faiola F, **Pereira CF**, Ding J, Saunders A, Gingold J, Schaniel C, Lemischka IR, Silva JC, Wang J. Zfp281 mediates Nanog autorepression through recruitment of the NuRD complex and inhibits somatic cell reprogramming. *Proc Natl Acad Sci* USA 2012 Oct 2;109(40):16202-7.

21. Lee DF, Su J, Ang YS, Carvajal-Vergara X, Mulero-Navarro S, **Pereira CF**, Gingold J, Wang HL, Zhao R, Sevilla A, Darr H, Williamson AJ, Chang B, Niu X, Aguilo F, Flores ER, Sher YP, Hung MC, Whetton AD, Gelb BD, Moore KA, Snoeck HW, Ma'ayan A, Schaniel C, Lemischka IR. Regulation of embryonic and induced pluripotency by aurora kinase-p53 signaling. *Cell Stem Cell* 2012 Aug 3;11(2):179-94.
Highlighted in Nature Cell Biology *14*, 990 (2012).

22. Schnetz MP, Handoko L, Akhtar-Zaidi B, Bartels CF, **Pereira CF**, Fisher AG, Adams DJ, Flicek P, Crawford GE, Laframboise T, Tesar P, Wei CL, Scacheri PC. CHD7 targets active gene enhancer elements to modulate ES cell-specific gene expression. *PLoS Genetics* 2010 Jul 15;6(7):e1001023.

23. **Pereira CF**, Piccolo FM, Tsubouchi T, Sauer S, Ryan NK, Bruno L, Landeira D, Santos J, Banito A, Gil J, Koseki H, Merkenschlager M, Fisher AG. ESCs require PRC2 to direct the successful reprogramming of differentiated cells toward pluripotency. *Cell Stem Cell* 2010 Jun 4;6(6):547-56.
Recommended by the Faculty of 1000.

24. Kanhere A, Viiri K, Araujo CC, Rasaiyaah J, Bouwman RD, Whyte WA, **Pereira CF**, Brookes E, Walker K, Bell GW, Pombo A, Fisher AG, Young RA, Jenner RG. Short RNAs are transcribed from repressed polycomb target genes and interact with polycomb repressive complex-2. *Molecular Cell* 2010 Jun 11;38(5):675-88.
Recommended by the Faculty of 1000.

25. Landeira D, Sauer S, Poot R, Dvorkina M, Mazzarella L, Jorgensen HF, **Pereira CF**, Leleu M, Piccolo FM, Spivakov M, Brookes E, Pombo A, Fisher C, Skarnes WC, Snoek T, Bezstarosti K, Demmers J, Klose RJ, Casanova M, Tavares L, Brockdorff N, Merkenschlager M, Fisher AG. Jarid2 is a PRC2 component in embryonic stem cells required for multi-lineage differentiation and recruitment of PRC1 and RNA Polymerase II to developmental regulators. *Nature Cell Biology* 2010 Jun;12(6):618-24.

26. Santos J*, **Pereira CF***, Di-Gregorio A, Spruce T, Alder O, Rodriguez T, Azuara V, Merkenschlager M, Fisher AG. Differences in the epigenetic and reprogramming properties of

pluripotent and extra-embryonic stem cells implicate chromatin remodelling as an important early event in the developing mouse embryo. *Epigenetics & chromatin* 2010 Jan 12;3:1. *equal contributors.

27. Savarese F, Davila A, Nechanitzky R, De La Rosa-Velazquez I, **Pereira CF**, Engelke R, Takahashi K, Jenuwein T, Kohwi-Shigematsu T, Fisher AG, Grosschedl R. Satb1 and Satb2 regulate embryonic stem cell differentiation and Nanog expression. *Genes Dev* 2009 Nov 15;23(22):2625-38.

28. Banito A, Rashid ST, Acosta JC, Li S, **Pereira CF**, Geti I, Pinho S, Silva JC, Azuara V, Walsh M, Vallier L, Gil, J. Senescence impairs successful reprogramming to pluripotent stem cells. *Genes Dev* 2009 Sep 15;23(18):2134-9.

29. Correia MP, Cardoso EM, **Pereira CF**, Neves R, Uhrberg M, Arosa FA. Hepatocytes and IL-15: a favorable microenvironment for T cell survival and CD8+ T cell differentiation. *Journal of immunology* 2009 May 15;182(10):6149-59.

30. Jorgensen HF, Terry A, Beretta C, **Pereira CF**, Leleu M, Chen ZF, Kelly C, Merkenschlager M, Fisher AG. REST selectively represses a subset of RE1-containing neuronal genes in mouse embryonic stem cells. *Development* 2009 Mar;136(5):715-21.

31. **Pereira CF**, Terranova R, Ryan NK, Santos J, Morris KJ, Cui W, Merkenschlager M, Fisher AG. Heterokaryon-based reprogramming of human B lymphocytes for pluripotency requires Oct4 but not Sox2. *PLoS Genetics* 2008 Sep 5;4(9):e1000170.
    Highlighted in a Nuclear Reprogramming timeline by Yamanaka & Blau, Nature 2010.

32. Nunes RJ, Castro MA, Goncalves CM, Bamberger M, **Pereira CF**, Bismuth G, Carmo AM. Protein interactions between CD2 and Lck are required for the lipid raft distribution of CD2. *Journal of immunology* 2008 Jan 15;180(2):988-97.

33. Terranova R, **Pereira CF**, Du Roure C, Merkenschlager M, Fisher AG. Acquisition and extinction of gene expression programs are separable events in heterokaryon reprogramming. *Journal of Cell Science* 2006 May 15;119(Pt 10):2065-72.

34. Cabrita M*, **Pereira CF***, Rodrigues P, Cardoso EM, Arosa FA. Altered expression of CD1d molecules and lipid accumulation in the human hepatoma cell line HepG2 after iron loading. *FEBS journal 2005* Jan;272(1):152-65. *equal contributors.

35. Fonseca AM, **Pereira CF,** Porto G, Arosa FA. Red blood cells upregulate cytoprotective proteins and the labile iron pool in dividing human T cells despite a reduction in oxidative stress. *Free Radical Biology & Medicine* 2003 Dec 1;35(11):1404-16.

36. Fonseca AM, **Pereira CF,** Porto G, Arosa FA. Red blood cells promote survival and cell cycle progression of human peripheral blood T cells independently of CD58/LFA-3 and heme compounds. *Cellular Immunology* 2003 Jul;224(1):17-28.

Peer-reviewed research review articles and protocols:

1. Ascic E and **Pereira CF**. Transcription factor-mediated reprogramming to antigen-presenting cells. *Current Opinion Genetics & Development* 2024 Dec 24; 90:102300.
2. Zimmermannova O, Ferreira A, **Pereira CF**. Orchestrating an immune response to cancer with cellular reprogramming. *Genes & Immunity* 2024 Feb; 25(1):95-97.
3. Ferreira AG, Zimmermannova O, Kurochkin I, Ascic E, Åkerström F, **Pereira CF.** Reprogramming Mouse and Human Cancer cells to Antigen Presenting Cells. *Bio-Protocol,* 2023 Nov 20;13(22): e4881.
4. Zimmermannova O, Caiado I, Ferreira AG, **Pereira CF**. Cell fate reprogramming in the era of cancer immunotherapy. *Frontiers in Immunology* 2021 Jul 21;12:714822.
5. Ulmert I, Oliveira LH, **Pereira CF**, Lahl K. Mononuclear phagocyte regulation by the transcription factor Blimp-1 in health and disease. *Immunology* 2020 Dec; 161(4): 303–313.
6. Rosa FF, Pires CF, Zimmermannova O, **Pereira CF**. Direct Reprogramming of Mouse Embryonic Fibroblasts to Conventional Type 1 Dendritic Cells by Enforced Expression of Transcription Factors. *Bio-Protocol*, 2020 May 20;10(10):e3619.
7. Pires CF, Rosa FF, Kurochkin I, **Pereira CF**. Understanding and Modulating Immunity With Cell Reprogramming. *Frontiers in Immunology* 2019 Dec 11; *10*:2809.
8. Silvério-Alves R, Gomes AM, Kurochkin I, Moore KA, **Pereira CF**. Hemogenic Reprogramming of Human Fibroblasts by Enforced Expression of Transcription Factors. *J Vis Exp* 2019 Nov 4;(153).
9. Daniel MG, **Pereira CF**, Bernitz JM, Lemischka IR, Moore K. Reprogramming Mouse Embryonic Fibroblasts with Transcription Factors to Induce a Hemogenic Program. *J Vis Exp.* 2016 Dec; (118): 54372.
10. Kirkeby A, Perlmann T, **Pereira CF**. The Stem Cell Niche Finds Its True North. *Development* 2016 Aug 15;143(16):2877-81.
11. Daniel MG. **Pereira CF**, Lemischka IR, Moore KA. Making a Hematopoietic Stem Cell. *Trends in Cell Biology* 2016 Mar;26(3):202-214.
12. **Pereira CF***, Lemischka IR, Moore K. 'From blood to blood': de-differentiation of hematopoietic progenitors to stem cells. *EMBO J* 2014 Jul 17;33(14):1511-3. *corresponding author.
13. **Pereira CF***, Lemischka IR, Moore K. "There will be blood" from fibroblasts. *Cell cycle* 2014;13(3):335-6. *corresponding author.
14. **Pereira CF***, Lemischka IR, Moore K. Reprogramming cell fates: insights from combinatorial approaches. *Ann N Y Acad Sci* 2012 Aug;1266:7-17. *corresponding author.

15. Piccolo FM, **Pereira CF**, Cantone I, Brown K, Tsubouchi T, Soza-Ried J, Merkenschlager M, Fisher AG. Using heterokaryons to understand pluripotency and reprogramming. *Philos Trans R Soc Lond B Biol Sci.* 2011 Aug 12; 366(1575): 2260–2265.
16. **Pereira CF**, Fisher AG. Heterokaryon-based reprogramming for pluripotency. *Current Protocols in Stem Cell Biology 2009 Apr;Chapter 4:Unit 4B.1*.
17. Arosa FA, **Pereira CF,** Fonseca AM. Red blood cells as modulators of T cell growth and survival. *Current Pharmaceutical Design* 2004;10(2):191-201.

Editorials and interviews:

1. Kim J, Lopes M, **Pereira CF.** Reprogramming Stars #20: Uncovering tumor epigenetic changes and potential biomarkers with cancer reprogramming—An Interview with Dr. Jungsun Kim. *Cellular Reprogramming* 2025.
2. Jauch R, Lopes M, **Pereira CF**. Reprogramming Stars #19: Upgrading Cell Fate Conversions with Engineered Reprogramming Factors—An Interview with Dr. Ralf Jauch. *Cellular Reprogramming* 2024; Dec;26(6):147-152.
3. Mall M, Lopes M, **Pereira CF**. Reprograming Stars #18: Engineering cell fates and preventing disease by repressing unwanted plasticity – An Interview with Dr. Moritz Mall. *Cellular Reprogramming* 2024; Oct;26(5):125-131.
4. Tursun B, **Pereira CF**. Reprogramming Stars #17: Breaking Down the Barriers of Direct Reprogramming using a model organism – An Interview with Dr. Baris Tursun. *Cellular Reprogramming* 2024.
5. Silva JCR, **Pereira CF**. Reprogramming Stars #16: Reprogramming, from Cells to Embryos--An Interview with Dr. José Silva. *Cellular Reprogramming* 2024 Jun;26(3):85-90.
6. Stricker SH, **Pereira CF**. Reprogramming Stars #15: Colliding Cellular Reprogramming Paths- An Interview with Dr. Stefan Stricker. *Cellular Reprogramming* 2024 Apr;26(2):37-42.
7. Kotter Mark R, **Pereira CF**. Reprogramming Stars #14: Fast-Forwarding Cellular Reprogramming- An Interview with Dr. Mark Kotter. *Cellular Reprogramming* 2024 Feb;26(1):2-7.
8. **Pereira CF**. Pioneer of Cloning and Inspirational Figure for Cellular Reprogramming Scientists Sir Ian Wilmut (July 7, 1944-September 10, 2023). *Cellular Reprogramming* 2023 Oct;25(5):181-182.
9. Ottosson D, **Pereira CF**. Reprogramming Stars #13: Establishing Connections with Cellular Reprogramming-An Interview with Dr. Daniella Rylander Ottosson. *Cellular Reprogramming* 2023 Aug; 25(4):130-135.
10. Qian L, **Pereira CF**. Reprogramming Stars #12: At the Heart of In Vivo Reprogramming — An Interview with Dr. Li Qian. *Cellular Reprogramming* 2023 Jun;25(3):83-87.

11. Fidalgo M, Guallar D, **Pereira CF**. Reprogramming Stars #11: Teaming Up to Uncover the Epitranscriptomics of Reprogramming-An Interview with Dr. Miguel Fidalgo and Dr. Diana Guallar. *Cellular Reprogramming* 2023 Apr;25(2):45-50.
12. Lee DF, **Pereira CF**. Reprogramming Stars #10: Modeling Cancer with Cellular Reprogramming—An Interview with Dr. Dung-Fang Lee. *Cellular Reprogramming* 2023 2023 Feb;25(1):2-6.
13. Fossati V, **Pereira CF**. Reprogramming Stars #9: Spacing Out Cellular Reprogramming-An Interview with Dr. Valentina Fossati. *Cellular Reprogramming* 2022 Nov;24(6).
14. Galloway KE, **Pereira CF**. Reprogramming Stars #8: A Synthetic Biology Approach to Cellular Reprogramming - An Interview with Dr. Katie Galloway. *Cellular Reprogramming* 2022 Aug;24(4):151-162.
15. Wu J, **Pereira CF**, Lu YR. Reprogramming Stars #7: Dynamic Pluripotent Stem Cell States and Their Applications - An Interview with Dr. Jun Wu. *Cellular Reprogramming* 2022 Jun;24(3):105-110.
16. Pires CF, **Pereira CF**. Reprogramming Stars #6: A Venture Based in Cellular Reprogramming - An Interview with Dr. Cristiana Pires. *Cellular Reprogramming* 2022 Apr;24(2):57-62.
17. Leigh ND, **Pereira CF**. Reprogramming Stars #5: Regeneration, a Natural Reprogramming Process - An Interview with Dr. Nicholas Leigh. *Cellular Reprogramming* 2022 Feb;24(1):2-8.
18. Parmar M, **Pereira CF**. Reprogramming Stars #4: A Reprogramming Approach for Parkinson's Disease - An Interview with Dr. Malin Parmar. *Cellular Reprogramming* 2021 Dec;23(6):319-325.
19. Kaji K, **Pereira CF**. Reprogramming Stars #3: Mechanisms of IPS Reprogramming—An Interview with Dr. Keisuke Kaji, *Cellular Reprogramming* 2021 Oct;23(5):264-269.
20. Ahlenius H, **Pereira CF**. Reprogramming Stars #2: Reprogramming Towards Neural Lineages - An Interview with Dr. Henrik Ahlenius, *Cellular Reprogramming* 2021 Aug;23(4):200-205.
21. Tsubouchi T, **Pereira CF**. Reprogramming Stars #1: Genome Programming Through the Cell Cycle - An Interview with Dr. Tomomi Tsubouchi, *Cellular Reprogramming* 2021 Jun;23(3):153-157.
22. **Pereira CF**. Reprogramming, The Journal. *Cellular reprogramming* 2021 June 17; 23(3), 151–152.
23. Andersson R, **Pereira CF**, Bauden M, Ansari D. Is immunotherapy the holy grail for pancreatic cancer? *Immunotherapy* 2019 Dec;11(17):1435-1438.
24. Ivanova N, **Pereira CF,** Lee DF. Ihor R. Lemischka (1953-2017). *Cell Stem Cell* 2018, 22 (1), 16-17. *Dev Cell* 2018, 44 (1), 10-11. *Cell* 2018, 172 (1-2), 1-2.

Lund, 9th of February 2025
Carlos Filipe Ribeiro Lemos Pereira
